Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.
Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.
Med Clin (Barc). 2021 Aug 13;157(3):141-143. doi: 10.1016/j.medcli.2021.03.008. Epub 2021 May 29.
In the context of the global COVID-19 pandemic, the different clinical manifestations of this infection pose a challenge for healthcare professionals. Respiratory involvement, the main symptom of SARS-CoV-2 infection, means that other manifestations, such as neurological, take a back seat, with the consequent delay in diagnosis and treatment.
All COVID-19 patients admitted with neurological symptoms or diagnosed with encephalitis since March 2020 in a tertiary hospital in Zaragoza, Spain.
Two patients with COVID-19 infection confirmed by nasopharyngeal PCR and whose clinical picture consisted of neurological alterations compatible with encephalitis. Cerebrospinal fluid (CSF) microbiology was negative for bacteria and viruses, including SARS-CoV-2 but, given the clinical suspicion of encephalitis due to the latter, antiviral treatment with immunoglobulins and plasmapheresis was started early. Despite this, the evolution was not satisfactory.
COVID-19 encephalitis is a recently described clinical entity, whose pathophysiology is still unknown and no treatment with clinical evidence is available to date.
在全球 COVID-19 大流行的背景下，这种感染的不同临床表现给医疗保健专业人员带来了挑战。呼吸道受累是 SARS-CoV-2 感染的主要症状，这意味着其他表现，如神经系统表现，处于次要地位，从而导致诊断和治疗的延迟。
在西班牙萨拉戈萨的一家三级医院，所有因神经系统症状入院或自 2020 年 3 月以来确诊为脑炎的 COVID-19 患者。
两名 COVID-19 感染患者通过鼻咽 PCR 得到证实，其临床表现为与脑炎相符的神经系统改变。脑脊液（CSF）微生物学检查对细菌和病毒均为阴性，包括 SARS-CoV-2，但鉴于后者的临床疑似脑炎，早期开始使用免疫球蛋白和血浆置换进行抗病毒治疗。尽管如此，病情的发展仍不理想。
COVID-19 脑炎是一种最近描述的临床实体，其发病机制尚不清楚，迄今为止尚无具有临床证据的治疗方法。
